Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial

Disease

Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy
Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy
What's Going on with Vera Therapeutics Stock on Monday?
What's Going on with Vera Therapeutics Stock on Monday?
Innovent, Eli Lilly Partner to Commercialize Breast Cancer Drug in China
Innovent, Eli Lilly Partner to Commercialize Breast Cancer Drug in China
What's Going on with Vera Therapeutics Stock on Monday?
What's Going on with Vera Therapeutics Stock on Monday?
Innovent, Eli Lilly Partner to Commercialize Breast Cancer Drug in China
Innovent, Eli Lilly Partner to Commercialize Breast Cancer Drug in China
Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration
Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration
Jazz Pharmaceuticals' New Cancer Drug Drives $1.3 Billion Opportunity, Says Analyst
Jazz Pharmaceuticals' New Cancer Drug Drives $1.3 Billion Opportunity, Says Analyst

Disease Recent News

AstraZeneca Highlights Sustained Survival Benefit In Advanced Breast Cancer Study
AstraZeneca Highlights Sustained Survival Benefit In Advanced Breast Cancer Study
AstraZeneca reports updated SERENA-6 data showing camizestrant improved PFS, PFS2 and ctDNA clearance in advanced breast cancer.
Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study
Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study
Rezolute says 6 of 8 patients met the primary endpoint in its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism.
AstraZeneca Sees Encouraging Survival Trend In Liver Cancer Trial
AstraZeneca Sees Encouraging Survival Trend In Liver Cancer Trial
AstraZeneca's EMERALD-3 trial shows improved progression-free survival with STRIDE, lenvatinib and TACE in liver cancer.
GeoVax Stock Higher As Company Highlights MVA Platform For Ebola Threats
GeoVax Stock Higher As Company Highlights MVA Platform For Ebola Threats
GeoVax shares gain after the company highlighted its MVA vaccine platform's potential against Ebola and Marburg threats.
Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report
Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report
Cancer centers race to access Revolution Medicines' pancreatic cancer drug after trial data showed survival doubled.
Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study
Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study
Protara reports updated Phase 2 data showing durable responses and favorable safety for TARA-002 in bladder cancer patients.
Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding
Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding
Moleculin Biotech nears first MIRACLE trial data unblinding as Annamycin shows higher remission rates in relapsed AML patients.
Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back
Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back
Recursion Pharmaceuticals to update on FDA trial design for REC-4881 for FAP in the second half of 2026. Analysts expect potential upside from rare diseases.
Penny Stock Oncolytics Biotech Says Colorecatal Cancer Drug's Durability Tops Historical Benchmarks
Penny Stock Oncolytics Biotech Says Colorecatal Cancer Drug's Durability Tops Historical Benchmarks
Oncolytics shares rise as pelareorep shows 19.5-month response durability and higher response rates in colorectal cancer study.
Bristol Myers Secures FDA Nod For Opdivo Plus Chemo For Untreated Hodgkin Lymphoma
Bristol Myers Secures FDA Nod For Opdivo Plus Chemo For Untreated Hodgkin Lymphoma
FDA approves Opdivo combo by Bristol Myers Squibb for untreated Hodgkin Lymphoma, showing improved progression-free survival.
Novartis Strikes $3 Billion Deal For Next-Gen Breast Cancer Drug
Novartis Strikes $3 Billion Deal For Next-Gen Breast Cancer Drug
Novartis to acquire SNV4818 for $3 billion, targeting PIK3CA-mutated breast cancer with a potentially safer, precision-based approach.
Nvidia's Genomic Analysis Suite To Help Speed Up Residual Cancer Detection
Nvidia's Genomic Analysis Suite To Help Speed Up Residual Cancer Detection
Droplet Biosciences uses lymph fluid and NVIDIA Parabricks to detect residual cancer faster and cut analysis time and costs.
Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug
Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug
Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being tested for vitiligo and celiac disease, with new trial results expected in 2026.
Insmed Maps Aggressive 2026 As Newly Approved Lung Disease Drug Gains Traction, Pipeline Advances
Insmed Maps Aggressive 2026 As Newly Approved Lung Disease Drug Gains Traction, Pipeline Advances
Insmed outlines 2026 outlook, highlighting BRINSUPRI expansion, ARIKAYCE revenue guidance and multiple late-stage clinical milestones across its pipeline.
What's Going With Cancer Biotech Erasca Stock On Thursday?
What's Going With Cancer Biotech Erasca Stock On Thursday?
Erasca stock jumps then drops after reports link it to AbbVie and a possible Revolution Medicines buyout.
BioMarin Boosts Rare Disease Portfolio With Amicus Buyout, Stocks Rally
BioMarin Boosts Rare Disease Portfolio With Amicus Buyout, Stocks Rally
BioMarin acquires Amicus for $4.8B, expanding its rare disease portfolio with Fabry and Pompe therapies, in a deal expected to close Q2 2026.
Merck Cholesterol, Cancer Drugs May Enter FDA Fast-Track Program: Report
Merck Cholesterol, Cancer Drugs May Enter FDA Fast-Track Program: Report
FDA plans to fast-track reviews of two experimental Merck drugs under its priority voucher program, potentially accelerating approval timelines.
Merck's Keytruda-Padcev Combo Boosts Survival In Pivotal Bladder Cancer Trial
Merck's Keytruda-Padcev Combo Boosts Survival In Pivotal Bladder Cancer Trial
Merck says Keytruda plus Padcev improved survival and response rates versus chemotherapy in a Phase 3 muscle-invasive bladder cancer trial.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved